Description

CJC-1295 DAC enhances growth hormone and IGF-1 secretion, improves body composition by increasing muscle mass and reducing fat, supports faster recovery and healing, and provides anti-aging benefits, making it effective for performance, metabolic health, and overall well-being. (PMID: 16822960, PMID: 15817669, PMID: 16352683, PMID: 17018654).

CJC-1295 DAC Research Topics:

1. Increased Growth Hormone Secretion:

   CJC-1295 DAC enhances the secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), leading to prolonged and sustained increases in plasma GH levels. This helps promote muscle growth, improve recovery times, and enhance overall physical performance. (PMID: 16822960, PMID: 15817669)

2. Improved Body Composition:

   By boosting GH levels, CJC-1295 DAC aids in reducing body fat and increasing lean muscle mass. This makes it an effective option for those looking to improve body composition and metabolic rate. (PMID: 16352683, PMID: 17018654)

3. Enhanced Recovery and Healing:

   The peptide supports faster recovery from injuries and strenuous physical activities by promoting tissue repair and growth. This benefit is particularly useful for athletes and individuals with active lifestyles. (PMID: 16352683).

4. Longevity and Anti-Aging:

   CJC-1295 DAC helps in maintaining youthful levels of GH, which can have various anti-aging effects, including improved better sleep quality, and enhanced energy levels (PMID: 16822960).

Peer-Reviewed Studies 

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006).

The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.

• Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse

CJC-1295 Structure

Source:Oxford Academic

Sequence: Tyr-D-Ala-Asp-Ala-lle-Phe-Thr-Gln-Ser­Tyr-Arg-Lys-Val-Leu-Ala-G I n-Leu-Ser-Ala-Arg-Lys­Leu-Leu-G I n-Asp-1 le-Leu-Ser-Arg
Molecular Formula: C1s2H2s2N44042
Molecular Weight: 3367 .954 g/mol
PubChem CID: 56841945

CJC-1295-DAC Structure

s

Source: Oxford Academic

Sequence: Tyr-D-Ala-Asp-Ala-lle-Phe-Thr-Gln-Ser­Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys­Leu-Leu-Gln-Asp-lle-Leu-Ser-Arg-Lys-DAC Molecular Formula: C152H2s2N44042
Molecular Weight: 3647.954 g/mol
PubChem CID: 91976842

CJC-1295 DAC Research

CJC-1295 and Growth Hormone Release

As a derivative of GHRH, it should come as no surprise that CJC-1295 promotes the release of GH. Studies show that a single dose of CJC-1295 increases GH levels in mice by 2-10 times. Peak GH levels are reached approximately 2 hours after administration and the effects last for six days. Unlike other GH secretagogues, CJC-1295 preserves the normal physiologic release of GH [1]. That means that the normal circadian peaks and valleys seen in GH release remain intact and that CJC-1295 is a physiologic growth hormone-releasing factor.

Preserving the physiologic release of GH while influencing the maximum concentration of the hormone in the bloodstream is critical to ensuring enhanced effects without increased side effects. In particular, CJC-1295 has been demonstrated to preserve growth hormone’s physiologic effects of hyperplasia, hypertrophy, bone density, blood sugar, fat metabolism, protein synthesis, and myocardial(heart cell) function.

CJC-1295 and Growth

Studies in mice without normal GHRH physiology have shown that CJC-1295 preserves normal GH release[2]. This makes the peptide potentially useful as a therapy for abnormal growth in a variety of mammalian species, humans included. Preserving normal pulsatile release of GH is critical to ensuring proper release of downstream hormones, such as insulin-like growth factor-2 (IGF-1).

CJC-1295 and Infertility

Research from the early 1990s suggests that CJC-1295 and other GRF analogues may be useful in promoting ovulation in infertile female patients. Scientists have long known that ovulation is dependent on IGF-1 and it is also likely influenced by GH release and cycling. Research in animal models of superovulation has helped to confirm these theories by showing that both GH and IGF-1 levels rise significantly surrounding the time of ovulation. Further, these studies indicate that exogenous administration of GH secretagogues, like CJC-1295, is enough to cause appropriate ovulation [3]. There is some speculation that CJC-1295 and other analogues may even be useful in male infertility by helping to regulate sperm production. This latter hypothesis has yet to be tested.

CJC-1295 is a growth hormone secretagogue designed to have a long plasma half-life and to preserve the physiologic patterns inherent in the GH axis. On both accounts, the molecule has been a success.CJC-1295 has experienced limited interest in research settings due to the advent of several similar molecules and because of the proprietary nature of the molecule’s structure. Now that CJC-1295 can be manufactured at will, there is likely to be renewed interest in its properties, particularly as they apply to the increasingly frustrating problem of human infertility.

CJC-1295 exhibits moderate side effects and low oral and excellent subcutaneous bioavailability in mice. Per kg, dosage in mice does not scale to humans. CJC-1295 for sale at Life Link Research is limited to educational and scientific research only, not for human consumption. Only buy CJC-1295 DAC if you are a licensed researcher.

Article Author

The above literature was researched, edited, and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author

Dr. Dominique Bridon holds a Master of Science, in Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. He completed his Post-Doctoral Research at the University of California, Berkeley. He studied the potential of CJC-1295 as a long-lasting GRF analog and also held various leadership positions involving peptide research and technologies at Ipsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon has served as a Director for Enobia (acquired by Alexion) and Neuronax and as a member of the Scientific Advisory Board of Syntaxin (acquired by Ipsen) and Biosortia. He now brings 30 years of executive and scientific leadership experience to the Epivax Oncology team.

Dr. Dominique Bridon is being referenced as one of the leading scientists involved in the research and development of CJC-1295. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Life Link Research and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Dominique Bridon is listed in [4] under the referenced citations.

 Referenced Citations

1. M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persist during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. 
2. M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. 
3. A. Volpe, G. Coukos, A. Barreca, G. Giordano, P. G. Artini, and A. R. Genazzani, “Clinical use of growth hormone-releasing factor for induction of superovulation,” Hum. Reprod., vol. 6, no.9, pp. 1228–1232, Oct. 1991. 
4. Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin &Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique.(2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary In Rats: Identification of CJC-1295 as a Long Lasting GRF Analog.